Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04413123Phase 2Active Not Recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Role: lead

NCT03097328Phase 2Completed

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Role: lead

NCT05176288Phase 2Withdrawn

Avelumab, Palbociclib and Axitinib in Advanced RCC

Role: lead

All 3 trials loaded